Omnipod 5: What the Clinical Trial Data Shows

The FDA-cleared tubeless pump system showed meaningful improvements in time-in-range and A1C levels in clinical trials. Here's what the evidence actually demonstrated.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

technologydevicesmanagement

Key takeaways

Omnipod 5 is a tubeless insulin pump that works with Dexcom continuous glucose monitors and a smartphone app
In clinical trials, children aged 6–13 improved their time-in-range from 52% to 68% (roughly 4 extra hours per day) and lowered A1C from 7.7 to 7.0
Adults in trials increased time-in-range from 65% to 74% (about 2 extra hours per day) and reduced A1C from 7.2 to 6.8
The pump can hold up to 200 units of insulin and is approved for ages 6 and older with Type 1 diabetes

What Is Omnipod 5?

Omnipod 5 is a tubeless insulin pump system that received FDA clearance for people with Type 1 diabetes age 6 and older. Unlike traditional pumps, it has no tubing connecting the pump to your infusion set. The system includes the Omnipod pump itself, integration with Dexcom continuous glucose monitoring, and a smartphone app that lets you control insulin delivery.

Trial Results in Children

The pivotal clinical trial tested Omnipod 5 in children aged 6 to 13. Participants showed notable improvements: their time-in-range (blood sugar within target levels) increased from 52% to 68%—meaning roughly 4 additional hours per day with glucose in target range. Average A1C values dropped from 7.7% to 7.0%.

Trial Results in Adults

Adults using Omnipod 5 in the trial also saw improvements. Time-in-range increased from 65% to 74%, or about 2 extra hours per day within target range. Average A1C decreased from 7.2% to 6.8%. Both children and adults in the trial experienced less time with blood sugar above 180 mg/dL.

Key Features

Omnipod 5 holds up to 200 units of insulin and uses an algorithm to adjust insulin delivery. The pump works wirelessly with Dexcom CGM data, and the mobile app comes pre-loaded with the system for on-the-go management.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.